{"pmid":32371168,"title":"The topic of COVID-19 related liver injury needs more rigorous research.","text":["The topic of COVID-19 related liver injury needs more rigorous research.","Clin Gastroenterol Hepatol","Lv, Xiu-He","Yang, Jin-Lin","Deng, Kai","32371168"],"journal":"Clin Gastroenterol Hepatol","authors":["Lv, Xiu-He","Yang, Jin-Lin","Deng, Kai"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371168","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cgh.2020.04.073","topics":["Mechanism","Treatment","Diagnosis"],"weight":1,"_version_":1666138496427884546,"score":9.490897,"similar":[{"pmid":32364442,"title":"Rigor before speculation in COVID-19 therapy.","text":["Rigor before speculation in COVID-19 therapy.","Am J Physiol Lung Cell Mol Physiol","Welling, Paul A","Batlle, Daniel","Byrd, James Brian","Burrell, Louise M","South, Andrew M","Sparks, Matthew A","32364442"],"journal":"Am J Physiol Lung Cell Mol Physiol","authors":["Welling, Paul A","Batlle, Daniel","Byrd, James Brian","Burrell, Louise M","South, Andrew M","Sparks, Matthew A"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364442","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1152/ajplung.00152.2020","link_comment_for":"32207983","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496010551298,"score":50.721996},{"pmid":32274341,"pmcid":"PMC7132021","title":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","text":["Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19.","J Clin Transl Hepatol","Li, Jie","Fan, Jian-Gao","32274341"],"abstract":["An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19."],"journal":"J Clin Transl Hepatol","authors":["Li, Jie","Fan, Jian-Gao"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274341","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.14218/JCTH.2020.00019","keywords":["covid-19","clinical characteristics","liver injury","mechanism","sars-cov-2"],"locations":["Wuhan","China","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1666138491651620864,"score":47.034622},{"pmid":32075364,"title":"[Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy].","text":["[Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy].","The outbreak of novel coronavirus pneumonia(NCP) caused by 2019 novel coronavirus has become a global public health challenge. Some patients accompany with liver function damage in addition to the main typical respiratory symptom. Here we analyzed the clinical features, susceptible population, potential causes and therapeutic strategies of NCP related liver injury.","Zhonghua Gan Zang Bing Za Zhi","Hu, L L","Wang, W J","Zhu, Q J","Yang, L","32075364"],"abstract":["The outbreak of novel coronavirus pneumonia(NCP) caused by 2019 novel coronavirus has become a global public health challenge. Some patients accompany with liver function damage in addition to the main typical respiratory symptom. Here we analyzed the clinical features, susceptible population, potential causes and therapeutic strategies of NCP related liver injury."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Hu, L L","Wang, W J","Zhu, Q J","Yang, L"],"date":"2020-02-21T11:00:00Z","year":2020,"_id":"32075364","source":"PubMed","week":"20208|Feb 17 - Feb 23","doi":"10.3760/cma.j.issn.1007-3418.2020.02.001","keywords":["angiotensin converting enzyme2","liver injury","novel coronavirus pneumonia","sever acute respiratory syndrome coronavirus 2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490834780160,"score":45.077522},{"pmid":32403255,"title":"COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.","text":["COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.","The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted.","J Clin Med","Kukla, Michal","Skonieczna-Zydecka, Karolina","Kotfis, Katarzyna","Maciejewska, Dominika","Loniewski, Igor","Lara, Luis F","Pazgan-Simon, Monika","Stachowska, Ewa","Kaczmarczyk, Mariusz","Koulaouzidis, Anastasios","Marlicz, Wojciech","32403255"],"abstract":["The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted."],"journal":"J Clin Med","authors":["Kukla, Michal","Skonieczna-Zydecka, Karolina","Kotfis, Katarzyna","Maciejewska, Dominika","Loniewski, Igor","Lara, Luis F","Pazgan-Simon, Monika","Stachowska, Ewa","Kaczmarczyk, Mariusz","Koulaouzidis, Anastasios","Marlicz, Wojciech"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403255","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/jcm9051420","keywords":["covid-19","mers","sars","sars-cov-2","coronavirus","liver","pandemic"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1666802845321527296,"score":43.953323},{"pmid":32425707,"pmcid":"PMC7230142","title":"COVID-19 related liver injury: call for international consensus.","text":["COVID-19 related liver injury: call for international consensus.","Clin Gastroenterol Hepatol","Ye, Zheng","Song, Bin","32425707"],"journal":"Clin Gastroenterol Hepatol","authors":["Ye, Zheng","Song, Bin"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425707","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cgh.2020.05.013","topics":["Diagnosis"],"weight":1,"_version_":1667252837724192768,"score":41.740776}]}